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Aim: Previous studies on outcome after transcatheter aortic valve implantation
(TAVI) have focused on the ﬁrst 30 days as well as ﬁrst year after the procedure.
Recently new left bundle branch block (LBBB) has been discussed to potentially have
a negative impact on long-term outcome. This study aimed at deﬁnition of the long-
term outcome up to 5 years after TAVI as well as the impact of new LBBB or need for
pacemaker implantation on outcome.
Methods: 376 consecutive patients with symptomatic aortic stenosis were prospec-
tively included. 205 patients were treated with a CoreValve prosthesis and 171
patients with an Edwards Sapien prosthesis. 167 patients developed a new LBBB or
needed a new pacemaker, in 209 patients neither a new LBBB was observed nor a new
pacemaker was required. Patients were followed-up on a yearly basis.
Results: Survival at 1 year follow-up was 81%, at two-year follow-up was 72%, at
three year follow-up 67% and at four year follow-up 60%. NHYA functional class
showed a marked improvement from 3.10.5 before TAVI to 1.80.7 at latest
follow-up. Impaired left ventricular function (ejection fraction <40%) before TAVI
was associated with impaired survival at follow-up (p¼0.012). There was no differ-
ence in long-term survival between patients with and without new LBBB or pace-
maker implantation (see ﬁgure).
Conclusion: Survival more than one year after TAVI is good with a yearly mortality
of less than 10%. A new LBBB or pacemaker implantation after TAVI has no negative
impact on long-term survival.C36 JACC VOP-081
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Introduction: Transcatheter aortic valve implantation (TAVI) has been a reliable
treatment modality for high risk patients with severe aortic stenosis (AS). TAVI has
high procedural success rates however some complications can occur during the
procedure. In this study, our aim is to present our experience with TAVI which is
a recently devoloping therapy in our country by demonstrating the clinical charac-
teristics of the patients and the complications related to the procedure.
Methods:We examined one month postprocedural results of 36 (20 women) high risk
patients with severe AS who had undergone TAVI in our clinic between 01 June 2012
and 31 May 2013. CoreValve (Medtronic Inc., Minneapolis, MN) or Edwards Sapien
XT (Edwards Lifesciences, Irvine, CA) bioprosthesis valves were implanted by
transfemoral approach to all parties.
Results: The mean age of the patients was 78.57.6 (range 55-91 years). Related
diseases of the patients and their risk scores are demonstrated in Table 1. Mean aortic
valve area was 0.60.1 cm2, and aortic valve gradients were 75.714.3 mmHg
(maximal) and 49.38.8 mmHg (mean). Femoral arterial access was achieved by
surgical cut down in 29 patients, and percutaneously (Prostar XL) in 7 patients (Table
2). Complications related to the procedure are demonstrated in Table 3. Two patients
(%5,6) had malapposition of bioprotesis into left ventricle and paravalvular aortic
regurgitation (AR) during the procedure requiring a second valve (CoreValve)
implantation. One patient had cardiac tamponade and treated with pericardiosentesis.
Vascular complication of femoral artery occurred in 5 (%13,9) of the patients
(Percutaneously Prostar XL was used in 3, and surgical cut down in 2 of patients).
Four patients need permanent cardiac pacemaker after TAVI (3 patients treated with
CoreValve, 1 patient with Edwards Sapien). Stroke occured in 1 patient who had
a second CoreValve bioprotesis due to malapposition of the ﬁrst bioprotesis. 3 (8,3%)
of the patients had paravalvular AR after TAVI. Ventricular septal defect which is
a rare complication after TAVI determined in 1 of the patients at the follow up period
treated with Edwards Sapien XT bioprotesis. There was no mortality during the
procedure, and at the 1 month follow-up period. However, at the 3 months of follow-
up 1 (0.02 %) cardiac death occured and 4 (11,1%) deaths observed due to noncardiac
causes (pneumonia, septic shock, renal failure, and head trauma).
Conclusion: TAVI is a reliable treatment modality alternative to surgery with low
incidence of complications, and high success rates for high-risk patients with severe
AS. Our experience is consisted with worldwide results. However there were rela-
tively low number of patients, the requirement of permanent pacemaker in CoreValve
procedures (11.54%) were lower than the reported incidence in literature.ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
Table 1. Demographics and baseline characteristics
Age (years) 78,5  7,6
Sex (M) 16 (44,4)
HT (%) 30 (83,3)
DM (%) 9 (25)
COPD (%) 18 (50)
PVD (%) 11 (30,6)
CABG (%) 9 (25)
Logistic Euroscore 36,4  14,3
Euroscore II 10,2  6,0
STS score 7,9  6,2
LVEF (%) 50,412,5
AV Area (cm2) 0,60,1
Peak AV Gradient (mm Hg) 75,714,3
Mean AV Gradient (mm Hg) 49,38,8
PAP (mm Hg) 45,312,6
HT¼Hypertension; DM¼Diabetes Mellitus; COPD¼Chronic Obstructive Pulmonary Disease;
PVD¼Peripheral Vascular Disease; CABG¼Coronary Artery Bypass Graft; LVEF¼Left Ventric-
ular Ejection Fraction; AV¼ Aortic Valve; PAP¼Pulmonary Arterial Pressure; AF¼Atrial Fibril-
lation; BBB¼Bundle Branch Block; PCI¼Percutaneous Coronary Intervention
Table 2. The types and sizes of the bioprotesis implanted and the femoral
access route
CoreValve 26 (%) 7 (19,4)
CoreValve 29 (%) 12 (33,3)
CoreValve 31 (%) 7 (19,4)
Edwards Sapien 23 (%) 1 (2,8)
Edwards Sapien 26 (%) 9 (25)
Percutaneous (Prostar XL) (%) 7 (19,4)
Surgical cut-down (%) 29 (80,6)
Table 3. Complications
Second valve implantation (%) 2 (5,6)
Vascular complication (%) 5 (13,9)
Paravalvular AR (< Mild) (%) 3 (8,3)
Stroke (%) 1 (2,8)
VSD (%) 1 (2,8)
All causes mortality (%) 4 (11,1)
Reversible LBBB (%) 3 (8,3)
Persistant LBBB (%) 5 (13,9)
Permanent Pacemaker 4 (11.1)
AR¼Aortic Regurgitation; LBBB¼Left Bundle Branch Block; VSD¼Ventricular Septal Defect
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Background: Combined surgical aortic valve replacement (SAVR) and coronary
artery bypass grafting (CABG) in patients with aortic stenosis (AS) and concomitant
coronary artery disease (CAD) is associated with increased operative risks. There is
little knowledge on the outcome associated with performing percutaneous coronary
intervention (PCI) in combination with transcatheter aortic valve implantation (TAVI).
Aim of Study: To investigate the outcome of combined TAVI and PCI in high-risk
patients with symptomatic high-grade AS and signiﬁcant CAD.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAMethods: From 1/2008 until 6/2012 338 consecutive patients (79.96.0 years,
logEuroSCORE 1811%) successfully treated with Medtronic CoreValve (n¼183),
Edwards-SAPIEN (n¼146) or Symetis Acurate bioprosthesis (n¼9) were
included in the analysis. 221 patients (66%) had CAD. 66 patients (19.5%, 33 female)
with signiﬁcant CAD underwent combined TAVI and PCI. In 58 patients (group A)
a staged approach of PCI a mean of 139 days prior to subsequent TAVI was chosen.
8 patients (group B) were treated in a single procedure with PCI ﬁrst. 272 patients
underwent only TAVI (group C).
Results: 30 daymortality for patients undergoing TAVI plus PCI was similar to patients
with isolated TAVI (12.1% vs. 9.9%; OR¼1.4, 95% CI 0.6-3.267; p¼0.436). 7 patients
(10.6%) of the TAVI plus PCI group had a periprocedural myocardial infarction
(NSTEMI) and stroke occurred in two patients (4.7%). There were no signiﬁcant
differences between TAVI plus PCI group vs. TAVI only group with regards to vascular
complications and postprocedure acute renal failure. Contrast volume at TAVI
implantation was higher in group B compared to group A patients (25160 vs. 17973
ml; p¼0.022).
Conclusion: CAD is frequent among patients with severe AS undergoing TAVI.
Revascularization with PCI can be safely performed in addition to TAVI either as
a staged or a concomitant intervention in this high-risk patient population.Pediatric Cardiology
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Introduction: Prostaglandin infusion treatment is of vital importance for keeping the
ductus arteriosus patency while waiting for either open surgery or invasive trans-
catheter intervention in duct-dependent congenital heart disease. Our study aimed at
deﬁning the lowest effective prostaglandin (PG) E1 dose in patients with inadequacy
of both pulmonary blood ﬂow and/or blood mixing (Group 1) and those with inad-
equate systemic blood ﬂow (Group 2).
Methods: Patients referred to our center within two weeks from birth following the
diagnosis of duct-dependent congenital heart disease and the start of i.v. prostaglandin
infusion were included in the study. Patients with inadequacy of both pulmonary blood
ﬂow and/or blood mixing (Group 1) and those with inadequate systemic blood ﬂow
(Group 2) were retrospectively evaluated in two separate groups with regard to the PG
E1 starting dose given in the referring facility, the lowest and the highest dose admin-
istered in our center, treatment duration, adverse effects and administered treatment.
Results: Of the 95 patients considered in the study, 69 (72.6%) belonged to Group 1
and 26 (27.3%) to Group 2. No difference between the groups could be detected as to
sex or birth weight (p¼0.95 and 0.42, respectively). A statistically signiﬁcant difference
could not be established for prostaglandin treatment duration, 9,730,81 days in Group
1 and 11.61.05 in Group 2 (p¼0.064). While the prostaglandin starting dose given to
both groups in the referring facility was 0.0670.003 mcg/kg/min, it was reduced after
titration to 0.0390.002 and 0.0810.005 mcg/kg/min, respectively, and this differ-
ence between the two groups was signiﬁcant (p<0.001). The dose administered to
Group 1 while ductus patency was being maintained was 0.00310.0001 compared to
0.00420.005 mcg/kg/min for Group 2, also a statistically signiﬁcant difference
(p<0.001). No adverse effects, including apnea, were observed during PG E1 infusion.
Conclusion: Our ﬁndings indicate that the infusion of prostaglandin at a very low
dose (0.003-0.005 mcg/kg/min) is sufﬁcient to maintain the patency of the ductus
arteriosus. A higher dose of PG E1 may be necessary in patients in patients with
inadequacy of both pulmonary blood ﬂow and/or blood mixing.
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Background and Aim: Congenital corrected transposition of the great arteries is
a group of clinically heterogeneous diseases because of numerous accompanyingLS C37
